ArticleFrontiers in psychiatry2026
Treatment continuation and factors associated with discontinuation with 3-month paliperidone palmitate in patients with schizophrenia: a
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Schizophrenia requires sustained treatment to prevent relapse and maintain functional stability. Poor adherence to oral antipsychotics is common and increases the risk of relapse and rehospitalization. Long-acting injectable antipsychotics, such as paliperidone palmitate 3-month formulation (PP3M), have been developed to improve adherence and clinical outcomes; however, evidence on clinical factors influencing treatment continuation and concomitant medication use in real-world settings remains limited. This Methods: Data from a multicenter, prospective post-marketing surveillance in Japan were used. Patients stabilized on paliperidone palmitate 1-month formulation for ≥4 months were transitioned to PP3M. Treatment continuation was assessed using Kaplan-Meier analysis, and factors associated with discontinuation were evaluated using multivariable Cox regression analysis. Mortality rates and treatment-related standardized mortality ratios (SMRs) were calculated, and concomitant medication patterns were analyzed descriptively. Results: A total of 891 patients were included. The previously reported 12-month treatment continuation rate was 84.7%. Patients without concomitant medications had significantly higher continuation rates than those with concomitant medications (85.3% versus 76.8%, Conclusions: PP3M demonstrated high treatment continuation in Japanese patients with schizophrenia, particularly those without concomitant medications. The lowest PP3M starting dose of 175 mg was associated with an increased risk of treatment discontinuation, underscoring the importance of individualized dosing strategies. Stable concomitant medication use supports symptomatic stability and the feasibility of PP3M monotherapy. These findings highlight the potential of PP3M to reduce pharmacologic burden and support long-term management of schizophrenia. Clinical trial registration: https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047973, identifier UMIN000042033.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.